secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001104659-25-122615
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi grants retention stock options to CEO, CMO, CFO; adopts severance plan
-----------------------------------------------------------------------------

- Board approved one-time retention options: CEO Imran Alibhai 47,500, CMO John Kauh 17,500, CFO Dan Conn 17,500 shares.
- Options vest 25% on Dec 16, 2026, then 36 equal monthly installments.
- New Severance Plan provides cash severance, COBRA, and equity acceleration on qualifying termination with or without Change in Control.
- CEO Alibhai eligible for 18 months salary plus 150% target bonus within Change in Control period; others 12 months salary plus 100% bonus.
- Plan supersedes prior severance agreements; participation requires signed release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925122615/0001104659-25-122615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925122615/tm2533917d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-122615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer